U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Adrenogenital syndrome

MedGen UID:
86215
Concept ID:
C0302280
Disease or Syndrome
Synonyms: Adrenogenital Syndrome; Adrenogenital Syndromes; Syndrome, Adrenogenital; Syndromes, Adrenogenital
SNOMED CT: Congenital adrenal cortical hyperplasia (237751000); Adrenogenital syndrome (267395000); Androgenital syndrome (267395000); Wilkins disease (271077003); Apert-Gallais syndrome (271077003); Adrenal virilism (271077003)
 
HPO: HP:0000840
Monarch Initiative: MONDO:0015898
Orphanet: ORPHA181412

Definition

Adrenogenital syndrome is also known as congenital adrenal hyperplasia, which results from disorders of steroid hormone production in the adrenal glands leading to a deficiency of cortisol. The pituitary gland reacts by increased secretion of corticotropin, which in turn causes the adrenal glands to overproduce certain intermediary hormones which have testosterone-like effects. [from HPO]

Term Hierarchy

Conditions with this feature

Deficiency of steroid 17-alpha-monooxygenase
MedGen UID:
82782
Concept ID:
C0268285
Disease or Syndrome
17 alpha(a)-hydroxylase/17,20-lyase deficiency is a condition that affects the function of certain hormone-producing glands called the gonads (ovaries in females and testes in males) and the adrenal glands. The gonads direct sexual development before birth and during puberty and are important for reproduction. The adrenal glands, which are located on top of the kidneys, regulate the production of certain hormones, including those that control salt levels in the body. People with 17a-hydroxylase/17,20-lyase deficiency have an imbalance of many of the hormones that are made in these glands. 17a-hydroxylase/17,20-lyase deficiency is one of a group of disorders, known as congenital adrenal hyperplasias, that impair hormone production and disrupt sexual development and maturation.\n\nHormone imbalances lead to the characteristic signs and symptoms of 17a-hydroxylase/17,20-lyase deficiency, which include high blood pressure (hypertension), low levels of potassium in the blood (hypokalemia), and abnormal sexual development. The severity of the features varies. Two forms of the condition are recognized: complete 17a-hydroxylase/17,20-lyase deficiency, which is more severe, and partial 17a-hydroxylase/17,20-lyase deficiency, which is typically less so.\n\nMales and females are affected by disruptions to sexual development differently. Females (who have two X chromosomes) with 17a-hydroxylase/17,20-lyase deficiency are born with normal external female genitalia; however, the internal reproductive organs, including the uterus and ovaries, may be underdeveloped. Women with complete 17a-hydroxylase/17,20-lyase deficiency do not develop secondary sex characteristics, such as breasts and pubic hair, and do not menstruate (amenorrhea). Women with partial 17a-hydroxylase/17,20-lyase deficiency may develop some secondary sex characteristics; menstruation is typically irregular or absent. Either form of the disorder results in an inability to conceive a baby (infertility).\n\nIn affected individuals who are chromosomally male (having an X and a Y chromosome), problems with sexual development lead to abnormalities of the external genitalia. The most severely affected are born with characteristically female external genitalia and are generally raised as females. However, because they do not have female internal reproductive organs, these individuals have amenorrhea and do not develop female secondary sex characteristics. These individuals have testes, but they are abnormally located in the abdomen (undescended). Sometimes, complete 17a-hydroxylase/17,20-lyase deficiency leads to external genitalia that do not look clearly male or clearly female. Males with partial 17a-hydroxylase/17,20-lyase deficiency may have a small penis (micropenis), the opening of the urethra on the underside of the penis (hypospadias), or a scrotum divided into two lobes (bifid scrotum). Males with either complete or partial 17a-hydroxylase/17,20-lyase deficiency are also infertile.
Deficiency of steroid 11-beta-monooxygenase
MedGen UID:
82783
Concept ID:
C0268292
Disease or Syndrome
Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency is an autosomal recessive disorder of corticosteroid biosynthesis resulting in androgen excess, virilization, and hypertension. The defect causes decreased synthesis of cortisol and corticosterone in the zona fasciculata of the adrenal gland, resulting in accumulation of the precursors 11-deoxycortisol and 11-deoxycorticosterone; the latter is a potent salt-retaining mineralocorticoid that leads to arterial hypertension (White et al., 1991). CAH due to 11-beta-hydroxylase deficiency accounts for approximately 5 to 8% of all CAH cases; approximately 90% of cases are caused by 21-hydroxylase deficiency (201910) (White et al., 1991).
Congenital lipoid adrenal hyperplasia due to STAR deficency
MedGen UID:
83341
Concept ID:
C0342474
Disease or Syndrome
Lipoid congenital adrenal hyperplasia, the most severe disorder of steroid hormone biosynthesis, is caused by a defect in the conversion of cholesterol to pregnenolone, the first step in adrenal and gonadal steroidogenesis. All affected individuals are phenotypic females with a severe salt-losing syndrome that is fatal if not treated in early infancy (summary by Lin et al., 1991 and Bose et al., 1996).
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
MedGen UID:
424833
Concept ID:
C2936858
Congenital Abnormality
21-hydroxylase deficiency (21-OHD) is the most common cause of congenital adrenal hyperplasia (CAH), a family of autosomal recessive disorders involving impaired synthesis of cortisol from cholesterol by the adrenal cortex. In 21-OHD CAH, excessive adrenal androgen biosynthesis results in virilization in all individuals and salt wasting in some individuals. A classic form with severe enzyme deficiency and prenatal onset of virilization is distinguished from a non-classic form with mild enzyme deficiency and postnatal onset. The classic form is further divided into the simple virilizing form (~25% of affected individuals) and the salt-wasting form, in which aldosterone production is inadequate (=75% of individuals). Newborns with salt-wasting 21-OHD CAH are at risk for life-threatening salt-wasting crises. Individuals with the non-classic form of 21-OHD CAH present postnatally with signs of hyperandrogenism; females with the non-classic form are not virilized at birth.
Glucocorticoid-remediable aldosteronism
MedGen UID:
824577
Concept ID:
C3838731
Disease or Syndrome
Familial hyperaldosteronism type I (HALD1), also referred to as glucocorticoid-remediable aldosteronism (GRA), is an autosomal dominant disorder characterized by hypertension, variable hyperaldosteronism, and abnormal adrenal steroid production, including 18-oxocortisol and 18-hydroxycortisol (Lifton et al., 1992). There is significant phenotypic heterogeneity, and some individuals never develop hypertension (Stowasser et al., 2000). Genetic Heterogeneity of Familial Hyperaldosteronism Familial hyperaldosteronism type II (HALD2; 605635) is caused by mutation in the CLCN2 gene (600570) on chromosome 3q27. Familial hyperaldosteronism type III (HALD3; 613677) is caused by mutation in the KCNJ5 gene (600734) on chromosome 11q24. Familial hyperaldosteronism type IV (HALD4; 617027) is caused by mutation in the CACNA1H gene (607904) on chromosome 16p13.

Professional guidelines

PubMed

Detmar S, Hosli E, Dijkstra N, Nijsingh N, Rijnders M, Verweij M
Birth 2007 Sep;34(3):238-44. doi: 10.1111/j.1523-536X.2007.00176.x. PMID: 17718874
Emerson RE, Ulbright TM
Semin Diagn Pathol 2005 Feb;22(1):33-50. doi: 10.1053/j.semdp.2005.11.003. PMID: 16512598
New MI
Dev Pharmacol Ther 1990;15(3-4):200-10. doi: 10.1159/000457647. PMID: 2099900

Recent clinical studies

Etiology

Waterloos M, Claeys T, Sempels M, Van Laecke E, Hoebeke P, Spinoit AF
J Pediatr Urol 2018 Apr;14(2):198-199. Epub 2018 Mar 8 doi: 10.1016/j.jpurol.2018.02.011. PMID: 29551555
Silver RI
Adv Exp Med Biol 2004;545:45-72. doi: 10.1007/978-1-4419-8995-6_4. PMID: 15086020
Sciarra F, Tosti-Croce C, Toscano V
Minerva Endocrinol 1995 Mar;20(1):63-8. PMID: 7651284
New MI
Dev Pharmacol Ther 1990;15(3-4):200-10. doi: 10.1159/000457647. PMID: 2099900
Leung AK
Am J Dis Child 1986 Mar;140(3):249-51. doi: 10.1001/archpedi.1986.02140170075033. PMID: 3946356

Diagnosis

Naouar S, Braiek S, El Kamel R
Presse Med 2017 Jun;46(6 Pt 1):572-578. Epub 2017 May 23 doi: 10.1016/j.lpm.2017.05.006. PMID: 28549629
Oliva E, Young RH
Semin Diagn Pathol 2000 Nov;17(4):340-58. PMID: 11202549
Sciarra F, Tosti-Croce C, Toscano V
Minerva Endocrinol 1995 Mar;20(1):63-8. PMID: 7651284
New MI
Dev Pharmacol Ther 1990;15(3-4):200-10. doi: 10.1159/000457647. PMID: 2099900
Kannan CR
Dis Mon 1988 Oct;34(10):601-74. doi: 10.1016/0011-5029(88)90023-5. PMID: 3053076

Therapy

Naouar S, Braiek S, El Kamel R
Presse Med 2017 Jun;46(6 Pt 1):572-578. Epub 2017 May 23 doi: 10.1016/j.lpm.2017.05.006. PMID: 28549629
Hakki T, Bernhardt R
Pharmacol Ther 2006 Jul;111(1):27-52. Epub 2006 Jan 19 doi: 10.1016/j.pharmthera.2005.07.006. PMID: 16426683
Khanna A, Kurtzman NA
Respir Care 2001 Apr;46(4):354-65. PMID: 11262555
Clements DB
Br J Ophthalmol 1971 Apr;55(4):275-8. doi: 10.1136/bjo.55.4.275. PMID: 5572270Free PMC Article
RAITI S, NEWNS GH
Arch Dis Child 1964 Aug;39(206):324-33. doi: 10.1136/adc.39.206.324. PMID: 14206872Free PMC Article

Prognosis

Waterloos M, Claeys T, Sempels M, Van Laecke E, Hoebeke P, Spinoit AF
J Pediatr Urol 2018 Apr;14(2):198-199. Epub 2018 Mar 8 doi: 10.1016/j.jpurol.2018.02.011. PMID: 29551555
Sedý J, Nanka O, Spacková J, Jarolím L
J Sex Med 2008 Jul;5(7):1572-81. doi: 10.1111/j.1743-6109.2008.00796.x. PMID: 18331256
Khanna A, Kurtzman NA
J Nephrol 2006 Mar-Apr;19 Suppl 9:S86-96. PMID: 16736446
Silver RI
Del Med J 2000 Aug;72(8):343-7. PMID: 10984977
Larsson A
Ups J Med Sci Suppl 1987;44:231-6. PMID: 3481902

Clinical prediction guides

Waterloos M, Claeys T, Sempels M, Van Laecke E, Hoebeke P, Spinoit AF
J Pediatr Urol 2018 Apr;14(2):198-199. Epub 2018 Mar 8 doi: 10.1016/j.jpurol.2018.02.011. PMID: 29551555
Lima M, Ruggeri G, Randi B, Dòmini M, Gargano T, La Pergola E, Gregori G
J Pediatr Surg 2010 Oct;45(10):2087-91. doi: 10.1016/j.jpedsurg.2010.05.016. PMID: 20920736
Ashley RA, McGee SM, Isotaolo PA, Kramer SA, Cheville JC
J Urol 2007 Feb;177(2):546-9; discussion 549. doi: 10.1016/j.juro.2006.09.041. PMID: 17222630
DeCherney AH
J Womens Health Gend Based Med 2000;9 Suppl 1:S9-13. doi: 10.1089/152460900318803. PMID: 10695868
New MI
Dev Pharmacol Ther 1990;15(3-4):200-10. doi: 10.1159/000457647. PMID: 2099900

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...